India gold demand rises on restocking
MUMBAI (Reuters) - Gold demand in India, the world's biggest buyer of the metal, picked up on Monday as buyers were scrambling to purchase limited stocks available with local banks after most overseas sellers left for the Christmas vacation.
* The actively traded gold contract for February delivery on the Multi Commodity Exchange (MCX) was 0.26 percent lower at 30,832 rupees per 10 grams as of 4:01 p.m.
* "Demand is good. Buyers are placing orders for limited stocks with banks. They (buyers) know the supply situation will remain tight for the next few days. Overseas suppliers are going on leave," said a Mumbai-based dealer with a state-run bank.
* "Buyers are also comfortable with prices. They are not hesitating in making deals below 31,000 rupees. Jewellers are restocking," the dealer said.
* The rupee, which rose on Monday, plays an important role in determining the landed cost of the dollar-quoted yellow metal.
* Overseas gold ticked up a little in thin pre-holiday trade on Monday as equities regained some strength, but prices stayed near their weakest in four months as the U.S. fiscal stalemate drove investors to the sidelines.
* The March silver contract on the MCX was down 0.13 percent at 58,087 rupees per kg.
(Reporting by Rajendra Jadhav; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- CBI drops coal scam case against Kumar Mangalam Birla
- India's growth speeds up in after-glow of Modi's triumph
- Saudi king warns of terrorism threat to U.S., Europe
- Exclusive: Reliance plans $13 billion projects including new refinery
The Central Bureau of Investigation (CBI) has closed a coal scam case against billionaire Kumar Mangalam Birla and a former top bureaucrat that emerged in 2012 after an auditor's report on revenue loss to the exchequer from allocations of coal blocks. Full Article
Exclusive: Reliance plans $13 billion projects including new refinery. Full Article
In race for bigger margins, drug makers willing to lose the India "advantage". Full Article